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Abstract
Angiogenesis has a critical role in physiologic and disease processes. For the growth of tumors, angiogenesis must
occur to carry sufficient nutrients to the tumor. In addition to growth, development of new blood vessels is
necessary for invasion and metastases of the tumor. A number of strategies have been developed to inhibit tumor
angiogenesis and further understanding of the interplay between tumors and angiogenesis should allow new
approaches and advances in angiogenic therapy. One such promising angiogenic approach is to target and inhibit
angiogenesis with vaccines. This review will discuss recent advances and future prospects in vaccines targeting
aberrant angiogenesis of tumors. The strategies utilized by investigators have included whole endothelial cell
vaccines as well as vaccines with defined targets on endothelial cells and pericytes of the developing tumor
endothelium. To date, several promising anti-angiogenic vaccine strategies have demonstrated marked inhibition
of tumor growth in pre-clinical trials with some showing no observed interference with physiologic angiogenic
processes such as wound healing and fertility.
Introduction
Cancer mortality is related to the spread of neoplastic
cells to distant loci where the cells, supported by existing
blood vessels and angiogenesis, proliferate and give rise
to secondary tumors. Tumor angiogenesis is up-regulated
by a number of conditions including hypoxia, hypoglyce-
mia, mechanical disruption, and genetic and inflamma-
tory alterations [1] that lead to activation of growth
factors and pro-angiogenic genes [2,3]. The stringent reg-
ulation of angiogenesis in normal tissues is often lacking
in tumor angiogenesis, resulting in immature and leaky
tumor vessels. Furthermore, compared to the tissue-
vessel distribution in normal tissue, there is an uneven
distribution of vessels within tumors, leading to tumor
hypoxia and inefficient transport of chemotherapeutic
drugs. In contrast to normal endothelial cells, in which
the vast majority are quiescent, tumor endothelial cells
actively proliferate, driven by hypoxia and increased
levels of angiogenic factors and their cognate receptors.
These differences between quiescent and angiogenic
endothelial cells resulted in the first clinical anti-angio-
genesis trial on human cancer two decades ago. There
are now several anti-angiogenic therapies that have
received FDA approval including sunitinib, sorafenib, and
bevacizumab; and with more than 40 anti-angiogenic
drugs in clinical trials [4], further advances are antici-
pated [5-11].
Differences among tumor endothelial cells and non-
malignant endothelial cells may not only be quantitative
but in some instances may also be qualitative. With
serial analysis of gene expression, investigators com-
pared gene expression from endothelial cells isolated
from normal or malignant tissue, and found that several
transcripts (e.g., CD276) were specifically elevated in the
tumor endothelium [12,13]. Although most receptors/
proteins that are increased in the tumor endothelium
are also up-regulated in physiologic angiogenic pro-
cesses, CD276 is not increased in the vessels of wounds
or the corpus luteum [13]. Nevertheless, CD276 is not
completely specific for the tumor endothelium because
its expression may be induced by cytokines on the cell
surfaces of B cells, T cells, and dendritic cells. There are
also many proteins/receptors in tumor endothelial cells
that are overexpressed (such as VEGFR2 and survivin)
compared to expression in quiescent endothelial cells.
Proteins differentially expressed on tumor endothelial
cells or the supporting matrix are attractive targets for
vaccine strategies, with the goal of breaking tolerance to
self-antigens.
Targeting the tumor vasculature with vaccines as well
as with other immunotherapies may have several poten-
tial advantages over targeting tumor cells. First, tumor
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tem than are tumor cells at a distance from the vessels.
Second, endothelial cells of the tumor are usually more
stable genetically than tumor cells, thereby reducing the
risk of resistance developing to immunotherapies [14,15].
Chromosomal abnormalities, however, have been identi-
fied in endothelial cells of solid tumors [16,17], and in
glioblastomas, the tumor cells and its endothelium are
derived from common cancer stem-like cells [18,19].
Third, down-regulation of MHC I in tumor cells occurs
less frequently in tumor endothelial cells, thereby leading
to a more potent CD8+-mediated response. Fourth, since
inhibition of a single endothelial cell can inhibit up to
100 tumor cells [20,21], immunotherapies directed
toward tumor endothelial cells have the potential of an
amplifying inhibitory effect.
As a result of these putative advantages and differen-
tially expressed proteins in the tumor endothelium, a
number of immunotherapeutic strategies have targeted
angiogenesis, including monoclonal antibodies, vaccina-
tions, and adjuvant co-stimulatory therapies [1]. The
most successful of these approaches, thus far, has been
passive immunotherapy by utilizing monoclonal antibo-
dies. In 2004, the monoclonal antibody bevacizumab
which targets angiogenesis through VEGF received
approval for treatment of colorectal cancer [22]. Bevaci-
zumab has also shown efficacy against other cancers
including lung, renal, and breast cancers [23,24]. It is
likely that the success and ability of bevacizumab to
selectively target tumor endothelial cells has provided
impetus to development of other forms of angiogenic
immunotherapies. Several promising preclinical studies
of tumor endothelial vaccines have led to clinical trials
that are primarily in phase I. In the burgeoning field of
tumor immunotherapies, we will focus on tumor vac-
cines that have a major anti-angiogenic component.
Delivery Systems of Tumor Endothelial Vaccines
As this review will highlight, there are many promising
tumor endothelial vaccines with demonstrated efficacy
in various animal models. These vaccines have been
delivered by different approaches/vectors, including
direct inoculation of peptides or “naked DNA”,g e n e
gun with gold particles, intradermal electroporation,
tumor or dendritic cell-based vectors, and attenuated
live bacteria vectors. The particular delivery system for
anti-angiogenic vaccine therapy is selected at least in
part based on whether immunizations are comprised of
peptides/proteins, DNA, or RNA. For peptide delivery
systems, the peptide can be inoculated directly into the
animal model along with an adjuvant, or dendritic cells
can be pulsed with the peptides before their inoculation.
For gene therapy vaccine approaches, recombinant DNA
may be delivered alone ("naked DNA”), by non-viral and
viral carriers, or by eukaryotic and prokaryotic cells.
Although delivery systems for vaccines targeting tumor
endothelial cells generally mirror those targeting tumor
cells [25-29], there are exceptions such as the infrequent
use of viruses with tumor-endothelial vaccines. Never-
theless, we see no contraindication to using modified
herpes simplex or vaccinia viruses to augment the
immune response of endothelial vaccines as in tumor
cell vaccines.
To date, plasmids encoding angiogenic self-antigens are
the most common forms of nucleic acid to demonstrate
an anti-angiogenic effect in mouse models. Moreover,
bacteria have been the most frequently used delivery sys-
tem for plasmid-based vaccines (see reviews of [30,31]).
Of the 32 vaccines with specific targets covered in this
review, bacteria were the primary delivery vector in 11
studies, whereas direct inoculation of “naked” plasmid
DNA was the primary delivery system in 6 studies (see
T a b l e1 ) .S e v e r a la n i m a ls t u dies have demonstrated that
orally administered bacteria-based vectors with attenu-
ated, nonreplicating strains of Listeria or Salmonella
have the potential to prevent and treat cancer through
inhibition of angiogenesis [32-35]. Although safety con-
cerns are a factor in considering these bacterial delivery
systems, it is of note that one Salmonella enterica strain
has been approved by the FDA for vaccine use [30,36].
Moreover, several bacteria-based vaccines that had
marked anti-angiogenic and anti-tumor activity showed
little to no autoimmune response, at least in the animal
studies. Electroporation is also an appealing approach
that has been used with DNA or RNA vaccines that tar-
get the tumor endothelium [37,38]. Because of the high
number of antigen presenting cells, the skin is a common
route of delivery for varied delivery systems including
electroporation. The intradermal DNA vaccination
approach enables long-term immune protection against
tumor angiogenesis and growth. Although electropora-
tion has been used less frequently than direct inoculation
of plasmid DNA, it may be more effective. For example,
intradermal electroporation of “naked DNA” gave a
much stronger anti-angiogenic and anti-tumor immune
response to survivin compared to intramuscular DNA
injection [37,39,40].
Besides tumor cells [41], dendritic cells (DC) pulsed
with peptide/protein epitopes (or DNA encoding these
epitopes) have also been employed successfully to vacci-
nate animals against tumor endothelial antigens [42,43].
DC process and present antigens to T and B cells and
produce cytokines and chemokines which in turn acti-
vate NK cells [44]. DC-based therapies involve modifica-
tion with pulsed (loaded) defined peptides, whole
protein lysate, and/or transfected DNA or RNA [42,43].
An interesting anti-cancer and anti-angiogenic approach
was the use of a VEGFR2-loaded DCs that led to greater
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TARGET FORM OF THE
VACCINE
TUMORS Vector/Route MECHANISMS Other Comments REFERENCES
Endothelial Cell Targets
VEGFR2 mVEGFR2-AP fusion
protein
Melanoma and lung
carcinoma
DC pulsed Ab, CTL
Primarily CD8
+
P Li Y et al.,
2002
[45]
Autologous DNA
vaccine- full-length
mVEGFR2
Melanoma, colon
carcinoma, non-small
cell lung carcinoma,
hepatoma
S. typhimurium,
oral
CTL Modest delay in wound healing
P, T
Niethammer
AG et al.,
2002 [59]
Xenogeneic DNA
vaccine
Murine melanoma,
carcinoma,
fibrosarcoma, lyphoma
“Naked” DNA,
SC
Ab, CTL, CD4
+(Th1)-
mediated
Quail VEGFR2 vaccine
Increased levels of IgG2a and 2b
P, T
Liu, J-Y et al.,
2003
[130]
Autologous DNA
vaccine- mVEGFR2
fragment
Breast tumor-rat Her2
expressing carcinoma;
murine p53- deficient
breast carcinoma
L.
monocytogenes,
oral
CD8+
mediated Inf-g
Elispot
Encodes listerolysin-VEGFR2
fragment; No effect on wound
healing or pregnancy
P, T
Seavey MM
et al., 2009
[32]
Autologous DNA
minigene
Murine breast and
colon carcinomas
S. typhimurium,
oral
CTL Encodes H-2Kd or H-2Dd
restricted peptides
P
Luo Y et al.,
2007 [63]
Autologous DNA
minigene
Murine lung, prostate,
and breast cancers
S. typhimurium,
oral
CTL Plasmid also encodes HIV-TAT
peptide
P
Zhou H et
al., 2005 [61]
H-2D
b -restricted
Peptides
Murine colon
carcinomas
SC CTL adjuvant (GM-CSF, CD40 Ab);
T
Dong Y et
al., 2006
[62]
HLA-A2 or-A24
restricted hVEGFR2
Peptides
Mouse melanoma and
colon carcinomas
ID CTL HLA-24 restricted Peptide 169
(RFVPDGNRI) induced human
PBMC-CTL lysis of endothelial
cells
Wada S et
al., 2005 [43]
VEGFR2 Peptide 169 +
gemcitabine
Pancreatic cancer
(Phase I)
SC CTL;
Reduced Treg
cells
Adjuvant (IFA) Miyazawa M.
et al., 2009
[66]
Xenogeneic DNA
vaccine
Murine breast and
colon carcinoma
Cationic
liposomes, IV
Ab, CTL Human VEGFR2;
P, T
Xie K et al.,
2009 [65]
Autologous DNA
vaccine (VEGFR2 fused
with b-defensin 2)
Murine lung and colon
cancer
Cationic
liposomes, IM
Ab, CTL Antitumor and anti-angiogenic
synergy between VEGFR2 and b-
defensin-2;
P, T
Wang YS
et al., 2007
[64]
Autologous DNA
vaccine- Extracellular
Domain
Murine Lung S. typhimurium,
oral
Ab, CTL CD4+
(Th1), C8+
mediated
Increased levels of IgG2a and 2b
P
Zuo SG et al.,
2010 [67]
VEGF Xenogeneic DNA
vaccine
Fibrosarcoma, breast
cancer, hepatoma
“Naked” DNA,
IM
Ab
CD4
+-mediated
Xenopus VEGF has about 75%
homology with humans and
mice
P, T
Wei YQ et al.,
2001 [58]
Autologous or
xenogeneic protein
Murine and human
colon caricinoma;
human rhadosarcoma
IM Ab; h- or mVEGF conjugated to KLH
P
Rad FH et al.,
2007 [73]
FGFR-1/bFGF Autologous bFGF
peptide
Murine melanoma and
lung carcinoma
Lipid A
containing
liposomes
IM
Ab Effective vaccine against the 44
aa segment of the heparin
binding domain; No effect on
wound healing or pregancy
P
Plum SM et
al., 2000 [76]
Plum SM et
al., 2004 [77]
Xenogeneic DNA
vaccine
Murine fibrosarcoma,
hepatoma and breast
cancer
“Naked” DNA,
IM
Ab FGFR-1 from Xenopus laevis
Delayed wound healing
P, T
He QM et al.,
2003 [78]
TEM8 Autologous TEM8 with
rat Her2 or human
tyrosinase-related
protein1 DNA vaccine
Rat Her-2 expressing
breast carcinoma;
Murine melanoma
Gold-particle
gene gun
No Ab or CTL
response with
TEM8 vaccine
alone
Synergy observed
P
Felicetti P
et al., 2007
[82]
Matejuk et al. Vascular Cell 2011, 3:7
http://www.vascularcell.com/content/3/1/7
Page 3 of 21Table 1 Different Strategies Utilized With Tumor Endothelial Vaccines (Continued)
Xenogeneic DNA
vaccine
Murine melanoma S. typhimurium
oral
CTL; Human TEM8
No effect on wound healing
T
Ruan Z et al.,
2009 [83]
ENDOGLIN
(CD105)
Xenogeneic protein Murine lung,
melanoma, colon
carcinoma,
fibrosarcoma
SC Ab; Synergy with cis-platinum;
adjuvant (alum)
P, T
Tan GH et al.,
2004 [87]
Tan GH et al.,
2004 [88]
ANGIOMOTIN Xenogeneic DNA
vaccine, full-length
Her-2 expressing breast
cancer in transgenic
mice
Electroporation,
TC
Ab Human angio-motin and Her-2;
antitumor synergy when
combined with Her-2 DNA
vaccine
Holmgren L
et al., 2006
[38]
TIE2 Xenogeneic protein
vaccine
Murine hepatomas and
melanomas
SC Ab Chicken Tie2
P, T
Luo Y et al.,
2006 [94]
DNA vaccine encoding
HLA-restricted
peptides
In vitro lysis of
endothelial cells
expressing Tie-2;
Tumor response not
tested
Gold-particle
gene gun
CTL HLA-A*0201/Kb transgenic mice;
the epitope
(FLPATLTMV) had the highest
CTL response;
Ramage JM
et al., 2004
[95]
HP59/SP55 Xenogeneic peptides Murine lung carcinoma Not stated Ab HP59 and SP55 peptide mixture
P
Fu C et al.,
2001 [96]
Pericyte Targets
HMW-MAA Xenogeneic DNA
vaccine, HMW-MAA
fragment
Murine melanoma,
renal carcinoma, Her-2
transgenic mice
L
monocytogenes
IP
Ab, CTL HMW-MAA (2160-2225 aa)
fragment fused to LLO
T
Maciag PC et
al., 2008 [33]
PDGFRb Autologous DNA
vaccine, full-length
Murine colon, breast,
lung carcinoma
S. typhimurium
oral
CTL Also, targets activated fibroblasts
P, T
Kaplan CD et
al., 2006 [34]
Combined Targets
SURVIVIN Xenogeneic DNA
vaccine
Murine melanoma Electroporation,
ID
CTL Human survivin vaccine
P
Lladser A et
al., 2010 [37]
Survivin/CCL21 DNA
vaccine
Murine lung carcinoma S. typhimurium,
oral
CTL Mouse survivin; no effect on
wound closure or fertility
P, T
Xiang R et
al., 2005 [35]
GRP Recombinant chimeric
HSP-65 -GRP6 fusion
protein
Murine breast
carcinomas
SC Ab, CTL 6 tandem repeats of GRP(18-27
aa) fused to HSP-65
P, T
Guojun W et
al., 2008
[115]
Chimeric-HSP65-GRP6
DNA Vaccine
Murine melanoma “Naked” DNA,
IM
Ab chimera also includes tetanus
toxoid and HSP70 fragments;
P
Fang J et al.,
2009 [116]
LEGUMAIN Allogeneic DNA
vaccine
Murine non-small lung,
colon and breast
cancers
S. typhimurium,
oral
CTL Mutant polyubiquitin
incorporated
P, T
Luo Y et al.,
2006
[119]
Autologous DNA
minigene
Murine breast
carcinoma
S. typhimurium,
oral
CTL Angiogenesis inhibited more
90%; H-2K vaccine more potent
than H-2D
P
Lewen S et
al., 2008
[120]
MMP-2 Xenogeneic full-length
MMP-2 DNA vaccine
Murine fibrosarcoma,
hepatoma, lung
carcinoma
“Naked” DNA,
IM
Ab Chicken MMP-2
P, T
Su JM et al.,
2003 [123]
b3 Integrin Xenogeneic b3 DNA
vaccine
Murine fibrosarcoma,
mammary carcinoma
“Naked” DNA,
IM
Ab Chicken b3 ligand binding
domain
P, T
Lou YY et al.,
2002 [129]
Abbreviations in table; Ab, antibody response; AP-alkaline phosphatase; CTL, cytotoxic T-lymphocyte response; m, mouse; h, Human; LLO, listerolysin; P, protective
vaccine approach in which pre-immunized mice show anti-tumor activity; T, therapeutic vaccine approach in which vaccine, administered after tumor inoculation,
has anti-tumor efficacy; keyhole limpet hemocyanin; SC, subcutaneous, ID, intradermal, IM, intramuscular, TC, transcutaneous
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tumor models [45]. Different forms of nucleic acids
have also been used for angiogenic peptides and pro-
teins. In addition to peptides, proteins, and recombinant
DNA, mRNA is another promising strategy to enhance
cellular immunity [46]. For example, antitumor synergy
was observed when dendritic cells were transfected with
mRNA from two receptors (VEGFR-2 and Tie2) that are
highly expressed on tumor endothelial cells [47]. Vary-
ing the routes of pulsed DC administration may also
affect the efficacy of tumor vaccines. Pellegatta and col-
leagues determined that glioblastomas regressed signifi-
cantly more when mice received both intratumoral and
subcutaneous pulsed DC injections compared to those
which received subcutaneous injections [48].
Although most authors have not compared different
carrier systems with one another, it is evident that the
carrier system and route of administration are critical
for the success of the vaccine in animal models and in
human clinical trials [49]. We have already discussed
differences in the immune response to survivin based on
whether electroporation or direct injection of DNA was
used. In addition, when Lai et al. compared three differ-
ent delivery approaches (gene gun with non-coated par-
ticles, gene gun with coated gold particles, and
intramuscular injection) for the EGFR plasmid vaccine,
the gene-gun with non-coated particle vaccine had the
greatest cytotoxic T-lymphocyte (CTL) response and
anti-tumor response [49]. Interestingly, the CD4+
response and the levels of EGFR-specific antibodies
were much greater with the coated gold particle
method. The required robust immune response to over-
come self-tolerance will no doubt eliminate several car-
riers, and perhaps autoimmunity will eliminate other
carriers. Which of the carriers can be translated success-
fully from the animal models to humans remains to be
determined. The delivery vehicle and the immune-adju-
vant will likely be as important as the selected angio-
genic antigen to obtain a successful tumor response in
humans.
Approaches for Anti-Angiogenic Vaccines
A goal of vaccination in anti-angiogenic therapies target-
ing tumors is to break immune tolerance to self-anti-
gens and induce specific, strong, and persisting immune
response leading to eradication of cancer. Complex net-
works created by several immune-competent cells such
as dendritic cells, B cells, cytotoxic CD8+ T, CD4+ T-
helper, and NK cells in combination with cytokines, che-
mokines and other immune mediators are required for
effective vaccines and immune reactions against cancer
(Figure 1). Two anti-angiogenic vaccine approaches have
shown promising results in reducing tumor growth and/
or metastases: endothelial cell vaccines that demonstrate
antitumor activity and vaccines targeting specific angio-
genic targets.
I. Endothelial Cell Vaccines
Whole Cell
In 2000, Wei et al. published a seminal report that
demonstrated the efficacy of an endothelial cell vaccine
targeting tumors [50]. Studies on tumor models with
fibrosarcoma, hepatoma, and breast cancer cells utilized
xenogeneic (human or bovine) paraformaldehyde-fixed
endothelial cells. In both prophylactic (immunizations
followed by tumor inoculation) and therapeutic (tumor
inoculation followed by immunization) settings, the
tumor growth was markedly inhibited in the three dif-
ferent tumor xenograft models in mice receiving the
xenogeneic human umbilical vein endothelial cell
(HUVEC) vaccine. In contrast, the syngeneic endothelial
vaccine had no effect on the growth of these tumors
compared to the phosphate-buffered saline treated con-
trol group. Moreover, there was at least a 70% survival
of mice injected with the xenogeneic vaccines in the
therapeutic setting for at least 80 days post tumor
inoculation. Several experiments indicated that the anti-
angiogenic and anti-tumor activity in mice immunized
with xenogeneic endothelial cells was achieved by induc-
tion of CD4+ T lymphocyte-dependent endothelial cell-
specific antibodies. Depletion of CD4+ cells abrogated
the antitumor activity of the xenogeneic vaccines,
whereas depletion of CD8+ and NK cells did not. More-
over, adoptive transfer of immunoglobulins from mice
vaccinated with xenogeneic cells resulted in marked
tumor inhibition. Further support for the effectiveness
of this humoral anti-cancer protection came from in
vitro studies where antibodies were able to block
endothelial cell proliferation and also from in vivo
experiments where angiogenesis was inhibited in a cor-
neal micropocket assay. These endothelial specific anti-
bodies most likely bind to the vascular endothelial
growth factor receptor 2 (VEGFR 2) and avb3 integrin.
In addition to the efficacy of xenogeneic vaccines, sev-
eral studies have demonstrated the anti-tumor efficacy of
syngeneic whole endothelial cell vaccines. If an adequate
immune response occurs, syngeneic endothelial cell vac-
cines may be preferable to xenogeneic vaccines because
there are fewer species-specific immune reactions. Okaji
and colleagues showed that the syngeneic endothelial
cell-based vaccine (hepatic sinusosoidal endothelium iso-
lated from BALB/c mice) arrested pulmonary metastases
in a murine colon cancer in both protective and thera-
peutic pre-clinical settings [51]. In addition to induction
of inhibitory antibodies that cross-reacted with human
and mouse endothelial membrane antigens, this vaccine
induced cytotoxic T-lymphocytes specific against
endothelial but not tumor cells. In contrast to the
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vaccine had modestly greater anti-tumor activity than did
the xenogeneic cell vaccine. The reason for disparity
between the two studies is not clear, but it might be due
to differences in the endothelial cells used in vaccine pre-
paration or the route of administration. Notably, the
microvasular hepatic sinusoidal endothelial cells in this
s t u d ym a yp r o v i d eam o r ee f f e c t i v ec e l l - b a s e dv a c c i n e
[51]. In the therapeutic experimental vaccine setting, this
was the only syngeneic cell vaccine study that showed
significant inhibition and/or prolonged survival in the
tumor-bearing mice [51]. A second study also demon-
strated the efficacy of syngeneic tumor endothelial vac-
cines. In this preclinical study, Scappaticci and Nolan
compared syngeneic, allogeneic, and xenogeneic
endothelial cell vaccines for their ability to provide pro-
tection against melanoma in a mouse model [52]. The
syngeneic endothelial cells were transformed by SV40 T
antigen and H-ras, while the allogeneic and xenogeneic
hemangioendothelioma cells had transformed sponta-
neously. Three weeks after the last intraperitoneal (ip)
injection of the transformed endothelial cells, the mice
Figure 1 Major mechanistic immune pathways of anti-angiogenic vaccines and their targets. Vaccine antigens are processed by antigen
processing cells such as dendritic cells and presented to T cells. Depending on the antigen, the route of administration, and the vector, peptide
presentation to either major histocompatibility complex (MHC) class I or II occurs, with subsequent interaction with T-cell receptors on CD4+ or
CD8+ cells. Cytotoxic CD8+ T cells recognize and lyse tumor endothelial cells directly by perforin-mediated and Fas-mediated cytotoxic
mechanisms. CD4+ T-helper cells, through release of different cytokines, can induce Th1 or Th2 responses that stimulate B-cells to produce
antibodies and/or activate NK cells and macrophages to inhibit tumor endothelium. Representative targets related to endothelial and cancer
cells and their environment for anti-angiogenic vaccines are depicted. Reprinted with permission, Cleveland Clinic Center for Medical Art &
Photography © 2010. All Rights Reserved.
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(B16F10) cells. All mice had a humoral immune response
to the different endothelial cell vaccines, with vaccinated
mice displaying a decrease of 45% in VEGF serum levels
compared to control. Furthermore, the group vaccinated
with syngeneic cells showed complete tumor inhibition
in 50% (3/6) of mice beyond 6 months, whereas mice in
untreated and other vaccinated treatment groups died
within 3 to 4 weeks post-tumor inoculation. In mice vac-
cinated with syngeneic cells that eventually developed
tumors, microvessel densityc o u n t sw e r e4 - 5f o l dl o w e r
than were those in the control groups. From adoptive
transfer experiments and CD8 knockout mice, the results
suggested that both humoral and cellular immunity were
important in the syngeneic vaccinated group. Interest-
ingly, the vaccinated long-term survivors were signifi-
cantly protected from a challenge with a different tumor
type (EL-4 lymphoma). More recently, prophylactic vac-
cination with a syngeneic transformed endothelial cell
line, Tpit/E, was shown to inhibit subcutaneous mela-
noma growth and appearance of lung metastasis in a
mouse model [53]. Because death ensued rapidly within 3
to 4 weeks after inoculation of the B16F10 melanomas,
therapeutic vaccination was not attempted with this
vaccine.
An anti-angiogenic endothelial cell vaccine has also
been tested for its anti-tumor activity in a pilot clinical
trial of patients who had recurrence of their brain
tumors or metastatic colorectal cancer. The patients
were treated with glutaraldehyde-fixed human umbilical
vein endothelial cells (HUVECs) by intradermal injection
every week for the first month and then every 2 weeks
[54]. Specific antibodies against HUVEC membrane
antigens were detected in eight out of total nine patients
and specific cellular immune responses against HUVEC
were detected in six of seven tested patients. In addition,
magnetic resonance imaging showed partial or complete
tumor responses for at least 9 months in three patients
with malignant brain tumors, while the three patients
with colorectal cancer showed no response. Because
there was not a direct correlation between degree of
immune response and anti-tumor activity, the authors
suggest that further studies are needed to identify fac-
tors that facilitate or mute immunity. Nevertheless, the
results of this trial were promising in view of the lack of
reported side effects and the response to treatment of
patients with recalcitrant tumors.
Endothelial cell membrane
Instead of using the whole endothelial cells as a vaccine,
rat tumor endothelial proteins were isolated from lumi-
nal surfaces of vascular endothelial cells containing sev-
eral up-regulated angiogenesis-associated endothelial
proteins [55]. In a rat lung metastatic model, endothelial
cell surface proteins were isolated in situ by
biotinylation followed by strepavidin selection. This mix-
ture of mostly undefined proteins was used as a xeno-
geneic vaccine to treat subcutaneous LLC tumors in a
mouse model. Although the growth of primary tumors
was not affected in vaccinated mice, the numbers of
lung and liver metastases were reduced by at least 75%.
T lymphocytes isolated from immunized mice lysed in a
dose-dependent manner endothelial but not tumor cells,
confirming specific anti-endothelial properties of this
vaccine; adoptive transfer of CTL in vivo did not have
anti-tumor activity, suggesting that local tumor condi-
tions may suppress their efficacy (e.g., intratumoral reg-
ulatory T-lymphocytes). In contrast, adoptive transfer of
the IgG antibody from vaccinated into naïve tumor-
bearing mice specifically targeted tumor endothelium,
reduced metastases, and prolonged life-span in a thera-
peutic model.
II. Vaccines Expressing Defined Targets
Defined endothelial vaccines are based on specific targets
and include peptides and nucleic acids (DNA or RNA)
that encode these peptides (see Table 1, Figure 2). Suita-
ble angiogenic targets in tumors may be receptors/mar-
kers on endothelial cells or alternatively, may be growth
factors secreted by cells other than endothelial cells. To
date, there has been no target or epitope that is comple-
tely specific for tumor endothelial cells. For example,
TEM8, one of the more specific tumor endothelial cell
markers identified thus far, was originally found in the
tumor vasculature and the developing embryo, but it has
since been found on cell surfaces of melanomas, breast
cancers, and dendritic cells. Despite the overlap in this
system, we think that classification of angiogenic vaccines
based on preponderance of their targets within most
tumors may be useful. As a result, we have divided tumor
endothelial vaccines with defined targets into three
classes: 1) growth factors/receptors or epitopes that are
primarily associated with growth of tumor endothelial
cells; 2) growth factors/receptors or epitopes that pro-
mote growth of pericytes; and 3) proteins/growth factors/
receptors that enhance both tumor and endothelial cell
growth or survival. The growth factors were classified,
not on their cells of origin, but on the location of their
receptors.
A. Endothelial cell targets
Vascular Endothelial Growth Factor Receptor-2
(VEGFR2) VEGFR2, also known as FLK-1 or KDR, is an
angiogenesis-associated receptor expressed on tumor
endothelial cells. Angiogenesis in non-tumor vessels is
relatively rare, enabling specific targeting of VEGFR2-
mediated tumor angiogenesis with minimal side effects.
VEGF-mediated signaling through VEGFR-2 is the key
rate-limiting step in tumor angiogenesis, and plays the
most important role in neovascularization, development,
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central role in physiologic angiogenesis as well as in vas-
culogenesis as demonstrated by the lack of vasculogen-
esis in VEGFR2 null mice [56]. VEGFR2 belongs to the
tyrosine kinase receptor family that includes VEGFR1,
VEGFR2, VEGFR3 and neutropilin 1. Since VEGFR2 is a
selective marker for neoplastic endothelium, it has been
a target for many approaches, including small molecule
kinase inhibitors, synthetic receptor tyrosine kinase inhi-
bitors, monoclonal antibodies, and vaccines [57]. More
vaccines and immunization strategies have been devel-
oped and tested in pre-clinical models against VEGF/
VEGFR2 than with any other tumor angiogenic marker
[43,45,58-67], and as a result, VEGF and VEGFR2 tar-
geting will be described separately.
In 2002, Li and colleagues were one of the first groups to
establish the utility of a VEGFR-2 vaccine to inhibit tumor
angiogenesis and growth [45]. After mice were immunized
with DC cells pulsed with a fusion AP-mouse VEGFR2
protein, they were challenged with two different tumors
(B16F10 melanoma or Lewis lung carcinoma) to establish
pulmonary metastases. In both tumor models, lung metas-
tases were reduced by more than 80% in mice that
received this vaccine. Moreover, angiogenesis in the algi-
nate assay was reduced by approximately 65%. Based on
depletion of CD4+ and CD8+ T-cell experiments, the
Figure 2 Tumor Endothelial Vaccines with Defined Targets. Schematic model of a tumor and its angiogenic vessels are shown with targets of
tumor endothelial vaccines. These vaccines may be classified on their specific targets 1) that are primarily associated with tumor endothelial cells,
2) that promote growth of pericytes, or 3) that enhance both tumor and endothelial cell growth or survival. Growth factors were classified based
on the location of their receptors. M, Macrophage. Reprinted with permission, Cleveland Clinic Center for Medical Art & Photography © 2011.
All Rights Reserved.
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primarily the result of CD8+ T-cells. Except for reductions
in the number of pregnancies and litter size, there were no
side effects from the vaccine.
Soon after, Niethammer et al. developed an oral autolo-
gous VEGFR2 DNA (pcDNA-3.1-Flk-1) vaccine carried
by attenuated S. typhimurium targeting tumor angiogen-
esis [59]. The vaccine significantly inhibited neovasculari-
zation in murine melanomas, colon carcinomas, and
non-small cell lung carcinomas and as a consequence the
vaccine suppressed metastases. In a therapeutic setting in
which a colon carcinoma cell line was injected iv, the
mouse (m) VEGFR2 vaccine reduced lung metastases by
approximately 70%. The endothelial cells expressing
VEGFR2 were specifically lysed by CD8+ T-cells from
VEGFR2 immunized mice. Whereas pregnancy was not
affected, wound healing was modestly delayed with this
therapy. More recently, Seavey and colleagues developed
an oral listeriolysin-mVEGFR2 DNA vaccine that
resulted in marked anti-tumor CTL-mediated inhibition
of Her-2-expressing breast cancer tumors (NT-2) in mice
[32]. After three listeriolysin-VEGFR2 plasmids were
made with non-overlapping mVEGFR-2 fragments, these
constructs were incorporated into Listeria monocyto-
genes. Four days after the mice were injected s.c. with
NT-2 cells, they received the initial vaccination and by
day 64 post tumor inoculation, there was approximately
a 70% reduction in tumor size in treatment groups vacci-
nated with two of the VEGFR2 constructs. There were
some mice in the vaccinated group that had no evidence
of tumors, but those vaccinated mice that did have
tumors had a marked reduction in the microvessel den-
sity of these tumors. Most interestingly, the anti-tumor
response from the mVEGFR2 vaccine was not solely
dependent on vascular targeting. The vaccine induced a
CTL-mediated response against the Her-2 antigen on
tumor cells which the authors attributed not to cross-
reactivity but to epitope spreading of Her-2. Epitope
spreading was hypothesized to be the result of destruc-
tion of tumor cells and release of tumor antigens (e.g.,
Her-2) owing to reduction in angiogenesis. There was no
effect on wound healing, and, in contrast to an earlier
study [45], the vaccine had no toxic side effects on
pregnancy.
Compared to large full-length coding VEGFR2 DNA
insert (> 4000 base pairs), a minigene DNA vaccine with
DNA encoding MHC-I-restricted peptides is a particu-
larly attractive approach to minimize side effects. Utiliz-
ing a restricted minigene approach in which five H2-D
d
and/or H-2K
d restricted peptides were inserted per plas-
mid construct, Luo et al. determined that an oral vac-
cine delivered by S. typhimurium protected against
tumors of different origin (D2F2, CT-26) in BALB/c
mice [63]. In a prophylactic experimental design, the
survival rate in vaccinated mice was about 4-fold greater
than in the control group. Some of the minigenes tested
had anti-tumor activity equivalent to the full-length
VEGFR2 vaccine. The vaccine was specific to VEGFR2
proliferating endothelial cells and lysed them in CTL-
specific manner. In a similar study, Zhou et al. demon-
strated the anti-tumor efficacy of VEGFR2 minigene
vaccine targeting H-2D
d-restricted VEGFR2 epitopes in
a different mouse strain (C57BL/6J) [61].
Many of the advantages that the minigene approach
offers are shared by the peptide vaccine approach. That
is, the small sizes of the peptides are likely to have less
toxicity and the sequences of the peptides can easily be
modified to optimize binding to MHC-I-like molecules.
Using binding algorithms and MHC binding assays, two
naturally processed CD8 T-cell epitopes (VILTNPISM
and FSNSTNDILI) were identified from murine VEGFR2
[62]. Cytotoxic T lymphocytes targeting endothelial cells
effectively reduced angiogenesis in a Matrigel assay and
inhibited tumor growth by approximately 50% in a thera-
peutic setting in mice [62]. Another study identified a
potent immunogenic epitope, VEGFR2-169 peptide
(RFVPDGNRI), that was able to evoke strong CTL
responses in cancer patients [43]. Indeed, the epitope
VEGFR2-169 vaccine in combination with gemcitabine
was tested in a phase I clinical trial for patients with
metastatic and unresectable pancreatic cancer [66]; 83%
of patients who completed one course of treatment
(4 vaccinations) developed immunological reactions at
the injection sites and in 61% patients, specific CTLs
against the vaccination peptide were detected. No severe
side reactions of grade 4 or higher were noted in the
clinical trial and grade 3 toxicities were caused by non-
vaccine therapies (e.g., gemcitabine). On the basis of not
identifying a dose-limiting toxicity in this trial for the
VEGFR-169 vaccine, the optimal dose in future clinical
trials should be 2 mg per individual or higher.
The results of two other studies will be discussed in
which cationic liposomes were the carriers and adjuvants.
Xie et al determined that a xenogeneic human VEGFR2
DNA vaccine had marked anti-tumor and angiogenic
activity in vivo [65]. In the therapeutic setting in which
mice had established murine breast or colon cancers,
60% of the group receiving the xenogeneic vaccine
survived for 2 months, while all mice in the control (dex-
trose-treated) group died by day 40. The VEGFR2-
containing plasmid was incorporated within cationic
liposomes and injected iv once a week for six injections.
In contrast to previous studies, the murine VEGFR2 had
little protective or therapeutic activity on tumor size or
growth in this study. This may be due to use of different
DNA delivery vectors, chemical/genetic adjuvants and/or
routes of administration. In a second study, cationic lipo-
somes were also used to incorporate a plasmid with a
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VEGFR2 to immunize tumor-bearing mice [64]. MBD2 is
an antimicrobial peptide, which augments innate and
adaptive immunity by activating Toll-like receptor 4 and
recruiting immature dendritic cells [68,69]. Three days
after Lewis Lung tumor cells were injected iv, the mice
received the first of four intramuscular injections of the
vaccine. Compared to the murine VEGFR2 vaccine, the
fusion vaccine resulted in mice with 50% fewer lung
metastases and in tumors with reduced angiogenesis.
Clearly, the fusion protein attached to the VEGFR2
greatly enhanced the activity of this vaccine.
Vascular Endothelial Growth Factor-A Based on alter-
native splicing, there are five pro-angiogenic variants of
vascular endothelial growth factor (VEGF-A) that target
and activate VEGFR1 and VEGFR2. The function of
each of these different forms of VEGF in tumor angio-
genesis is not completely known, but larger molecular
weight isoforms of VEGF-A (VEGF-A165, VEGF-A189)
in solid tumors may be associated with increased angio-
genesis, metastases, and a worse prognosis [70,71]. In
addition, VEGF is secreted by both tumor and endothe-
lial cells, but despite its origin, the primary target of
VEGF-A is its cognate receptors located on angiogenic
vessels.
Several different VEGF immunization vectors, includ-
ing plasmids, T7 recombinant phage, and proteins, have
demonstrated anti-tumor efficacy based on an antibody-
dependent response [58,72,73]. A DNA vaccine with the
Xenopus vascular endothelial growth factor was used to
induce anti-angiogenic and anti-tumor activity in a
mouse model [58]. Xenopus VEGF has an approximately
75% amino acid homology with VEGF from mice and
humans, making it a good vaccination candidate to
break tolerance. In both prophylactic and therapeutic
settings, this vaccine administered intramuscularly was
effective against several tumor-bearing models (MA
782/55 breast cancer, Meth A fibrosarcoma, and H22
hepatoma). In mice that were injected sc with tumor
cells 7 days before immunization, the survival rate at 90
days was between 50 and 60%, while mice from control
groups died before 50 days. Indicative of the central role
of CD4+ T-cells with this vaccine, adoptive transfer of
sera containing VEGF antibodies blocked tumor growth
and angiogenesis in vivo. Moreover, the anti-tumor
activity from the Xenopus VEGF vaccine was completely
eliminated with depletion of CD4+ cells, while depletion
of CD8+ and NK cells had no effect.
Similar to the previously discussed VEGF DNA vaccine
study [58,72,73], the “VEGF kinoid” vaccine, composed
of murine (m) or human (h) VEGF and keyhole limpet
hemocyanin, triggered a potent anti-VEGF antibody
response [73]. The (h, m) “VEGF kinoid” vaccine was
prepared by complexing VEGF with the immunogenic
carrier, limpet hemocyanin, in the presence of glutaralde-
hyde. In BALB/c mice immunized with VEGF-kinoid, the
number and size of lung metastases challenged with a
colorectal tumor were significantly decreased. In vitro,
the anti-VEGF antibodies from immunized mice inhib-
ited both proliferation of cultured HUVECs and the
binding of mVEGF to its receptor, VEGFR2. Moreover,
BALB/c mice immunized with hVEGF kinoid had high
levels of hVEGF antibodies in serum, and adoptive trans-
fer of purified IgG from these mice decreased by more
than 50% the size of tumors from different origins
(human A673 rhabdomyosarcoma, HT29 colon carci-
noma) in immunocompromised mice.
Notably, there are anti-angiogenic isoforms of VEGF-A
that differ from their angiogenic counterparts at the C-
terminal end [74,75]. Although the angiogenic isoforms
likely dominate in more angiogenic tumors, there is prob-
ably a balance between these isoforms in less vascular
tumors [75]. Consideration of these anti-angiogenic
isoforms of VEGF-A in vaccine development has thus
far been lacking. With further development of vaccines
against VEGF-A, avoidance of targeting these anti-
angiogenic forms will likely have an important role in
obtaining greater efficacy and specificity of the vaccine
with fewer undesired toxic effects. In addition to targeting
VEGF-A, other VEGFs such as VEGF-C and -D that pro-
mote tumor angiogenesis and lymphangiogenesis hold
promise but as of yet are untested vaccine targets.
FGFR-1/bFGF Fibroblast growth factor receptor-1
(FGFR-1, CD331) is a high affinity receptor for basic
fibroblast growth factor (bFGF, FGF2) and the signal
transduction pathway induced by the bFGF/FGFR-1
interaction has an important role in stimulating tumor
angiogenesis. Both bFGF and FGFR-1 have been tar-
geted by vaccines to reduce tumor size in pre-clinical
mouse models. Plum et al compared liposomal autolo-
gous bFGF peptide vaccines targeting either the heparin
binding domain (HBD) or the receptor binding domain
(RBD) of the growth factor [76]. Although the RBD vac-
cine had no anti-angiogenic or anti-tumor effect, the
HBD vaccine showed marked anti-angiogenic activity in
a gelfoam sponge model as well as anti-tumor activity.
In a metastasis model of murine B16 melanoma or
Lewis lung carcinoma cells, the HBD vaccine decreased
pulmonary metastases by more than 90%. Furthermore,
the primary anti-angiogenic mechanism of this vaccine
was the production of anti-FGF antibodies [76]. Notably,
this vaccine did not interfere with wound healing or
with reproduction [77].
Alternatively, He and colleagues used a xenogeneic plas-
mid DNA vaccine to target FGFR-1 and to break the
immune tolerance [78]. The amino acid sequence of Xeno-
pus FGFR-1 has homology of 74% and 80% with human
and mouse receptor, respectively. Intramuscular
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ing tumor cells subcutaneously (Meth A fibrosarcoma,
H22 hepatoma, or MA782/5 S breast cancer) led to an
80% or greater reduction in tumor size compared to the
control [78]. When the FGFR-1 vaccine was administered
7 days after inoculation of tumor cells, the mice had pro-
longed survival with significantly reduced tumor size com-
pared to controls. Whereas all the mice injected with the
three different tumors in the control groups had died by
day 50 after tumor cell injection, 80% of the mice in the
FGFR-1-vaccinated group were still alive. The vaccine
induced antibodies specific toward tumor endothelial cells
and the in vivo anti-tumor effect could be eliminated by
depletion of CD4+ T-cells. Except for delayed wound heal-
ing, there was no observed toxicity as measured by weight
loss, behavior, life-span or histology.
TEM8 With the serial analysis of gene expression
approach, tumor endothelial marker 8 (TEM8) was
identified as a specific cell surface marker for tumor ves-
sels. The physiologic function of TEM8 is not known,
although there is a specific interaction between TEM8
and the a3 subunit of collagen as determined by the
two-hybrid assay [79]. In contrast to most other
endothelial markers and/or receptors identified thus far,
the mRNA of TEM 8 was undetectable in the endothe-
lium of healing wounds or in the corpus luteum [12].
Consequently, TEM8 is a very specific marker for tumor
angiogenesis and is an ideal candidate for vaccine devel-
opment. Nevertheless, TEM8 is expressed in endothelial
cells of the developing embryo [80] and lung endothe-
lium [13], dendritic cells [81], melanomas, and breast
cancer [82].
Felicetti and colleages were the first group to develop
a TEM8 DNA vaccine [82]. Although the syngeneic
TEM8 vaccine injected into the stroma of rat Her2-
expressing breast cancer (233-VSGA1) was ineffective
when used alone, the combination of TEM8 and rat
Her-2 DNA vaccine was synergistic in reducing tumor
growth and extending tumor-free survival. Similarly, the
combination of TEM8 and tyrosinase-related protein-1
DNA vaccines were synergistic in their anti-tumor activ-
ity against B16F10 melanomas.
In contrast to previous studies, Ruan and colleagues
developed a TEM8 vaccine that did have anti-tumor
activity. In this study, a xenogeneic DNA vaccine encod-
ing human TEM8 carried by attenuated S. typhimurium
was tested for its anti-tumor activity in mice with B16F10
melanoma xenografts [83]. Oral administration of the
vaccine post-tumor challenge significantly decreased
tumor volume and prolonged life-span of vaccinated
mice. Whereas all mice had died at day 30 in the control
group injected iv with melanoma cells, none of the mice
in the TEM8-vaccinated mice had died and 60% of the
mice were alive at day 60. Additionally, experimental
pulmonary metastases were markedly reduced compared
to those in the control group. Experimental evidence
showed that the CD8 T-cell population was mainly
r e s p o n s i b l ef o rt h ei m m u n er e s p o n s e .N o t a b l y ,n ot o x i -
city from the TEM8 vaccine was observed as evidenced
by normal wound healing and neurological testing (ferti-
lity was not examined in this study). Because of the find-
ing that the expression of TEM8 is increased in
endothelial cells in the lungs of mice [13], more detail
studies are required to determine the safety of this
vaccine.
Endoglin (CD105) Endoglin, a 95-kDa cell surface pro-
tein expressed as a homodimer, functions as an accessory
protein for kinase receptor complexes of the TGF-b
superfamily and modulates TGF-b signaling. Expression
of endoglin is correlated with vascular density and poor
prognosis in patients with breast and colorectal carcino-
mas [84,85]. In addition to its expression on selected
tumors, endoglin is over-expressed on proliferating
endothelial cells in tumors and thus offers an attractive
target for anti-angiogenic therapy [86]. Tan et al. devel-
oped a xenogeneic (porcine) endoglin protein vaccine
administered in a tumor-bearing mouse model that
induced protective and therapeutic anti-tumor immunity.
The vaccine inhibited tumor growth and prolonged sur-
vival in a range of tumors including Lewis lung carci-
noma, B16 melanoma, CT26 colon carcinoma, and Meth
A fibrosarcoma. Deletion of CD4(+) T-lymphocytes abro-
gated the anti-tumor activity and endoglin-specific auto-
antibodies [87]. Moreover, the combination of low-dose
cisplatin with the endoglin vaccine showed at least addi-
tive anti-cancer and anti-angiogenic effects [88]. While
all murine CT26 carcinoma-bearing mice survived to day
50 in the combined vaccine-chemotherapy group, 60%
and 70% of the chemotherapy and vaccine-alone treated
mice, respectively, were alive. No toxicity was observed in
the mice treated with the vaccine or the vaccine-che-
motherapy groups. For instance, there was no difference
in weight, life-span, liver enzymes, white or red blood
cells counts, or tissue histology between the combined
vaccine-chemotherapy and the untreated groups.
Angiomotin The shorter splice variant of angiomotin,
p80 that is a membrane-associated protein is expressed
in tumor and placental endothelium and mediates
endothelial cell migration in vitro [89]. The anti-angio-
genic peptide, angiostatin, has high affinity with angio-
motin and inhibits its function by reducing endothelial
cell migration and tube formation in vitro [89,90]. The
role of angiomotin in endothelial cell migration and its
correlation with poor survival in breast cancer patients
[ 9 1 ]s u g g e s tt h a ti ti sap o t e n t i a lt a r g e tf o ra n t i - a n g i o -
genic immunotherapy. Indeed, targeting angiomotin by
DNA vaccination efficiently inhibited angiogenesis and
tumor growth in vivo. Since xenogeneic proteins
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mid expressing the human p80 isoform of angiomotin
was administered to different tumor-bearing mouse mod-
els. In an experiment in which the BALB/c mice were
electroporated transcutaneously with the angiomotin
construct before their challenge with breast cancer cells,
there was complete suppression of tumor growth in 12 of
18 mice more than 150 days [38]. In a similarly designed
experiment but in knockout B-cell mice, the anti-tumor
efficacy of the angiomotin vaccine was lost, indicating
that CD4+ cells and a humoral immune response were
essential. In a Her2/neu mouse model in which sponta-
neous breast cancers develop, there was no difference in
the number of tumor-free mice between the angiomotin-
vaccinated and the control mice; all mice in both groups
had tumors between the 20 and 25
th week of age. How-
ever, mice treated with a combination of angiomotin and
Her-2 vaccine were 80% tumor-free compared to 20% of
mice treated with the Her 2 vaccine alone when followed
up to 70 weeks after birth. In a Matrigel angiogenic
assay, the number of blood vessels was significantly
reduced in mice treated with the angiomotin vaccine. No
toxicity was observed with the angiomotin vaccine in
mice more than 1 year after it was administered.
TIE-2 Tie-2 is a receptor tyrosine kinase that is over-
expressed in activated tumor endothelial cells and has a
role in stabilizing interactions between pericytes and
endothelial cells in the tumor vasculature [92]. More-
over, administration of adenovirus expressing soluble
Tie-2, which is able to block activation of Tie-2, inhib-
ited growth of primary tumors and metastases [93].
These results suggest that Tie-2 could be a target for a
therapeutic vaccine and two studies suggest the poten-
tial of such a vaccine.
To overcome tolerance, a protein vaccine based on the
chicken Tie-2, which has about 70% amino acid homol-
ogy with mice and humans, was tested for its anti-tumor
and anti-angiogenic activity in a tumor-bearing mouse
model [94]. Both prophylactic and therapeutic vaccine
approaches with chicken-based TIE-2 reduced growth of
subcutaneous H22 hepatomas and B16F10 melanomas,
while vaccination with the mouse TIE-2 had no effect on
growth. Furthermore, mice that were immunized with
the chicken TIE-2 vaccine 7 days after tail vein injection
of B16 melanomas had a 75% reduction in metastases.
Indicative of a CD4+-mediated response, adoptive trans-
fer of purified antibodies from the immunized mice
results in an anti-tumor response in vivo and apoptosis
of endothelial cells in vitro. Moreover, depletion of CD8+
and NK cells did not alter the efficacy of the vaccine
whereas depletion of CD4+ cells eliminated its anti-
tumor activity. In addition to the apoptotic effect of anti-
bodies on endothelial cells in vitro, microvessel density in
the tumor and in the alginate encapsulation assay was
reduced indicating that anti-angiogenesis was the
primary effect of the vaccine.
In contrast to this study, Ramage et al. used a CD8
+-mediated strategy to induce HLA-A*0201-restricted
endothelial-specific CTLs in mice immunized with auto-
logous Tie-2 DNA vaccine [95]. Because HLA-A*0201
was one of the most frequent HLA-A alleles in humans,
Tie2 was screened for HLA-A*0201 binding epitopes;
four such peptides were identified and modified by
amino acid substitution (Z84, Z95, Z101, and Z107) to
enhance HLA binding and immunogenicity of these
epitopes. After plasmid constructs expressing the Tie-2
epitopes were made, HLA-A*0201 transgenic mice were
immunized with these constructs administered by a
gene gun. The construct containing the Z84 epitope was
most efficient in generating CTLs that were able to kill
human endothelial cells over-expressing Tie-2. The anti-
tumor activity of this vaccine approach has not been
reported.
HP59/SP55 SP55 and its human homolog, HP59, are
transmembrane proteins that share 86% homology [96].
HP59 is present in lung endothelium until 5 days after
birth [97,98], but after the neonatal period, HP59 is not
detected in normal vasculature of humans [96]. Never-
theless, HP59 is up-regulated in the vasculature of solid
tumors and rheumatoid arthritis. CM101, a polysacchar-
ide isolated from Group B streptococcus, is a ligand for
these two proteins and inhibits a number of tumors [96].
It is unlikely that HP59 or SP55 proteins are increased in
wound healing since their ligand, CM101, does not affect
wound healing. As a result of these findings of the selec-
tive increase of HP59 in tumor vessels, Fu et al examined
whether a xenogeneic peptide vaccine from HP59/SP55
would inhibit tumor growth in a mouse model [96]. After
receiving the HP59/SP55 peptide vaccine, the mice were
challenged with Lewis lung carcinoma cells; compared to
controls, the vaccinated mice had a tumor burden that
was 38% of control. Immunohistological evaluation of the
tumors indicated that the SP55/HP59 vaccine inhibited
not only tumor angiogenesis but also vasculogenesis.
B. Pericyte targets
HMW-MAA High Molecular Weight Melanoma-Asso-
ciated Antigen (HMW-MAA) is a surface chondroitin
sulfate proteoglycan with restricted distribution in nor-
mal tissue, but which is expressed in a wide range of
tumor tissues and is involved in progression and develop-
ment of metastases of melanoma cells. This antigen can
be used to target angiogenesis since HMW-MAA is
abundantly expressed on activated pericytes, which have
an essential role in neovascularization of tumors. Maciag
et al. generated a recombinant L. monocytogenes (Lm-
LLO-HMW-MAA-C) that contains and secretes a frag-
ment of HMW-MAA (residues 2,160-2,258) fused to the
first 441 residues of the listeriolysin O (LLO) protein
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melanoma cells that expressed full-length HMW-MAA,
the mice were immunized intraperitoneally with Lm-LL0
HMW-MAA-C vaccine; 62.5% (5 of 8) of mice were
tumor free on day 56 after tumor inoculation while no
mice in the control groups remained tumor-free. The
immunized mice that were tumor-free developed long-
term immunity as demonstrated by the rejection of a sec-
ond lethal dose of the melanoma cell line. Whereas the
control mice had developed tumors 10 days after tumor
inoculation, more than 90% of Lm-LLO-HMW-MAA-C
vaccinated mice rejected the cell line. Depletion of either
CD8+ or CD4+ cells abrogate dt h ep r o t e c t i v ee f f e c to f
the vaccine, indicating that both cell types were partici-
pating in the anti-tumor immunity. Notably, Lm-LLO-
HMW-MAA-C vaccine displayed anti-tumor effects
against several other cancers (the parent line, B16F10;
k i d n e yc a n c e r ,R E N C A ;at e ratocarcinoma NT-2) that
did not express HMW-MAA. In mice with HMW-MAA
negative tumors treated by the vaccine, pericytes were
significantly depleted in these tumors. These findings
suggest that pericytes in many tumors are the likely tar-
get of the vaccine.
PDGFR-b Another potential target over-expressed on
tumor pericytes is platelet derived growth factor receptor
beta (PDGFR-b). This signaling pathway is activated in
physiological processes such as embryonic development
and wound healing but this pathway is also up-regulated
in cancers [99,100]. In both tumors and embryos, angio-
genic endothelial cells expressing PDGFb recruit peri-
cytes to stabilize and remodel vessels. Furthermore, Song
and colleagues determined that reduction of PDGFRb-
expressing pericytes led to endothelial cell apoptosis, vas-
cular dilation, and decreased tumor volume in pancreatic
islet tumors in mice [101].
On the basis of these results, a strategy targeting peri-
cytes with a PDGFRb-based DNA vaccine was devel-
oped by Kaplan et al. [34]. This oral vaccine, delivered
by transformed S. typhimurium, reduced the number of
tumor-associated pericytes and protected mice from
colon, breast and lung carcinomas. In both prophylactic
and therapeutic settings, the tumor burden was reduced
by at least 60%. Moreover, in tumors implanted in mice
20 days before the oral vaccine was administered, the
vaccine was still surprisingly effective: the size of tumors
in the PDGFRb vaccine-treated group was about one-
fourth the size of the control groups (198 mm
3 vs. 898
mm
3). Although the intratumoral VEGF levels were
unchanged with the PDGFRb vaccine, the angiogenic
marker, isolectin B4-FITC, was significantly decreased in
bFGF-supplemented Matrigel assay. Based on standard
Cr-release assays from this study, the mechanism of the
tumor inhibition by the vaccine was due to a PDGFR-b-
specific CTL immune response.
C. Vaccines that target both endothelial and tumor cells
Survivin Survivin is an intracellular protein that inhibits
apoptosis. Although survivin is normally expressed dur-
ing embryonic development, it is not expressed in differ-
entiated cells. Nevertheless, survivin is up-regulated in
human cancer and tumor-associated endothelial cells to
avoid apoptosis. Thus, therapies including vaccines tar-
geting survivin induce apoptosis of tumor cells and their
angiogenic vessels [35,37,39,102]. In an early study,
naked DNA vaccines against full-length survivin admi-
nistered intramuscularly were found to have effective
humoral and cellular immune responses in mouse mod-
els [39]. Although the anti-tumor efficacy was not tested
in this study, Lladser’s group later reported that naked
DNA vaccination with survivin was less effective in pre-
venting tumors from developing in either the prophylac-
tic or therapeutic settings [37]. More effective delivery
systems for survivin vaccines have since been developed.
In a later study, Lladser’s group delivered the human
survivin DNA vaccine by intradermal electroporation
[37]. Against mouse B16 melanoma tumors, a xeno-
geneic DNA vaccine encoding human survivin induced
a cross-reactive cytotoxic response toward the mouse
survivin 20-28 epitope, suggesting that this vaccination
was able to break self-tolerance. In an in vivo angiogenic
Matrigel assay, the vascular density decreased nearly
50% in the survivin-vaccinated mice compared to the
plasmid control-vaccinated mice. In mice immunized
with survivin before tumor inoculation, 4 of 10 mice
remained tumor-free for 100 days while all vaccinated
control mice developed tumors and had died by day 30
after tumor cell challenge. In a second experimental
design in which the mice received their first immuniza-
tion 10 days after sc injection of B16 cells, there was
also a 40% protection in the survivin-vaccinated group.
In contrast to intradermal electroporation, naked DNA
vaccination with full-length survivin showed minimal
protection against tumor development.
An oral vaccine delivery system for a plasmid that
expressed survivin and the CCL21 chemokine was devel-
oped by Xiang et al [35]. CCL21 may synergize with the
survivin target through a number of its functions. By
attracting activated dendritic cells, enhancing T- cells
mediated immune responses, and inhibiting angiogenesis,
CCL21 through binding to its primary receptor CCR7
and to CXCR3 may synergize with the survivin target. To
optimize epitope processing by proteasomes and antigen
presentation to MHC-I, a mutant polyubiquitin was
included in the plasmid construct. The vaccine was deliv-
ered orally by an attenuated double mutated Salmonella
strain (dam
- and AroA
-) to eight mice with D121 murine
Lewis lung carcinoma. In the prophylactic setting, six
mice that received the survivin-CCL21 vaccine had no
evidence of pulmonary tumor metastases, while two
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tases. In contrast, seven of eight mice that received the
survivin alone vaccine developed metastases as did all
other groups (PBS, empty vector, and CCL21 alone treat-
ment group). A similar efficacy pattern was observed
with the therapeutic experimental design with the great-
est inhibition observed in mice that were vaccinated with
survivin-CCL21 vaccine. Mechanistic studies revealed
that survivin-CCL21-based vaccine triggered CTL-
mediated tumor cell apoptosis and significantly sup-
pressed angiogenesis in the tumor mass. In a Matrigel
assay that examined the anti-angiogenic effects of differ-
ent treatments in the absence of tumor cells, the survi-
vin-CCL21 vaccine-treated group reduced blood vessel
density by approximately 3-fold more than the control
groups. Moreover, CD8+ T-cells isolated from the survi-
vin-CCL21 treated group specifically lysed murine
endothelial cells that expressed survivin in vitro.
Although the survivin-CCL21 vaccine group markedly
inhibited tumor angiogenesis, it is of interest that angio-
genesis of wound healing and fertility were unaffected.
Gastrin Releasing Peptide/Gastrin Releasing Peptide
Receptor Gastrin Releasing Peptide (GRP), a 27-mer
amino acid peptide, is an autocrine/paracrine growth fac-
tor that belongs to the bombesin peptide family of neuro-
peptides involved in many steps of tumor progression
including angiogenesis. GRP is a strong mitogen that
augments the growth of several types of tumors including
breast, prostate, pancreatic, small cell lung, carcinoids,
and neuroblastomas [103-110]. By activating its receptor
(GRPR) located on both tumor and endothelial cells,
GRP is also a direct angiogenic factor as shown by
in vitro and in vivo angiogenic assays [111]. In addition,
GRP is able to contribute indirectly to tumor angiogen-
esis by augmenting expression of pro-angiogenic factors
such as IL-8 and VEGF [112,113]. The GRP antagonist,
77427, markedly inhibits endothelial cell cord formation
in vitro and inhibits angiogenesis in vivo [111]. Several
therapeutic strategies targeting GRP/GRPR, such as pep-
tide antagonists and monoclonal antibodies, have demon-
strated their antitumor efficacy in vitro and in vivo [114].
Recently, vaccines targeting GRP displayed an effective
anti-tumor response by inducing humoral and cell-
mediated immune responses. In this study, a recombi-
nant chimeric protein vaccine (HG6) containing six tan-
dem repeats of a GRP fragment (18 to 27 amino acids)
fused to the 65-kDa heat shock protein (HSP65) was
used to treat mice challenged with breast cancer [115].
The mycobacterial HSP65 was used to enhance humoral
immunity. In mice that were vaccinated with the GRP-
fusion HG6 protein before inoculation of breast cancer
cells (EMT-6), there was a 3-fold reduction in tumor size
compared to that of the control groups (phosphate buf-
fered saline or HSP65-vaccinated mice). Similarly, the
GRP reduced tumor size (approximately 2-fold) signifi-
cantly more than the control groups when mice received
the vaccine after-tumor inoculation. Also, there were
fewer blood vessels around each implant site from HG6-
immunized mice (37 vessels) than those from the
control-treated mice, PBS (125 vessels) and HSP65-
immunized mice (113 vessels). In an analogous approach,
a DNA vaccine encoding the GRP-HSP65 fusion product
showed anti-tumor activities in a prophylactic setting for
subcutaneous implanted tumors and a pulmonary metas-
tasis model [116]. Although the receptor of gastrin-
releasing peptide is a promising target, there have been
no pre-clinical studies on the utility of such a vaccine.
Nonetheless, there have been non-vaccine therapeutic
agents showing antitumor efficacy that have targeted
GRPR in mouse experiments [114].
Legumain This hypoxia-induced stress protein is an
asparaginyl endopeptidase that is over-expressed in
tumors, particularly in tumor-associated macrophages
(TAMs) but also in tumor endothelial cells and tumor
cells [117-119]. Legumain is located in the endosomal/
lysosomal pathway and cell surfaces of cancer cells,
tumor endothelial cells, and TAMs [117]. In contrast to
M1 macrophages that do not express legumain and have
immune-surveillance anti-tumor activity, most TAMs
are polarized M2 macrophages that promote tumor
growth and angiogenesis. When pro-tumor growth med-
iators such as IL-6, IL-10, MMP-9, and VEGF are the
primary secreted factors from TAMs, then tumor angio-
genesis, enhanced cell motility, and increased tumor cell
invasion are facilitated.
Luo et al. [119] constructed a DNA vaccine encoding a
legumain-mutant polyubiquitin fusion protein that was
incorporated within an attenuated S. typhimurium.T h e
vaccine was then tested in prophylactic and therapeutic
experimental models. In the prophylactic experiment, 1
week after receiving the last oral immunization, malig-
nant cell lines (breast, colon, and non-small lung) were
injected intravenously in the syngeneic mouse model.
Twenty-four days later, the number of lung metastases
was determined to be significantly lower in the legumain-
vaccinated mice. In the therapeutic experimental setting,
the mice were first challenged with breast cancer cells
(4T1) implanted subcutaneously and then immunized
with a legumain-based vaccine. After primary tumor
resection 12 days after initial injection, the mice were fol-
lowed up for 3 months. While 75% (6/8) of immunized
mice survived for 3 months, all mice in the control
groups were dead by 1 month; moreover, 62% (5/8) of
the immunized mice were totally free of metastases. Spe-
cific CD8+ CTL response toward TAMs and depletion of
CD8+ cells indicate that the efficacy of the vaccine was
primarily mediated by CD8+ cells. These results suggest
that legumain-based DNA vaccine induced specific
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DCs in Peyer’s patches, followed by MHC class I peptide
presentation. Vessel growth was significantly reduced
with the legumain vaccine with marked reduction in
proangiogenic factors released by TAMs such as TGF-b,
TNF-a,M M P - 9 ,a n dV E G F .B yr e m o v i n gt h ep r i m a r y
tumor, this vaccine strategy mirrors a suggested vaccine
approach for humans with metastatic disease.
An alternative to the full-length legumain gene vac-
cine is the approach utilizing legumain minigene vac-
cine [120]. The potential advantage of minigenes over
the full-length legumain is their ease of synthesis and
the lack of irrelevant antigenic epitopes, which can
cause serious side effects. On the basis of the binding
predictions of peptides to the MHC class I, two mini-
genes encoding legumain H-2D or H-2K restricted epi-
topes were evaluated for their anti-tumor and anti-
angiogenic effect. Although both minigenes showed
anti-tumor activity, the H-2K minigene vaccine showed
more activity. In a prophylactic setting, the H-2K mini-
gene vaccine inhibited local tumor growth (D2F2 breast
cancer cells) and metastases by approximately 50% and
75%, respectively, compared to empty vector control. In
addition, the H-2K minigene induced a specific and
potent anti-tumor immune response by activating CD8+
T-cells. Similar to the full-length legumain vaccine, the
minigene strategy abrogated TAMs from the tumor,
thereby reducing proangiogenic factors, which have key
roles in tumor angiogenesis. Notably, in a Matrigel
assay which was not dependent on the presence of
tumor cells, the H-2K minigene vaccine greatly reduced
angiogenesis by more than 90%. Unlike the full-length
vaccine, the minigene vaccine was not tested in a thera-
peutic setting.
MMP-2 MMP-2 (Matrix Metalloproteinase-2) belongs
to the MMP-family of enzymes responsible for tissue
remodeling, thereby allowing endothelial cells to migrate
and form new blood vessels [121]. Several studies have
shown a correlation between elevated levels of stromal
MMP-2 and increased aggressiveness and metastases of
some tumors [122]. Because there is high homology in
amino acid sequences of MMP-2 among chicken, mice,
and humans, a xenogeneic chicken MMP-2 was used as
the basis for a vaccine to overcome tolerance in treating
cancers in mice and humans [123]. Su et al. determined
that a DNA vaccine encoding chicken MMP-2 had pro-
tective and therapeutic anticancer activity against mur-
ine fibrosarcoma, hepatoma, and lung carcinoma. In
contrast, vaccination with the mouse MMP-2 had no
anticancer activity. In the prophylactic setting, there was
significant inhibition of tumor growth and prolonged
survival in mice who received the cMMP-2. There was
also a 50 to 77% reduction in lung metastases in the
cMMP-2 vaccine-treated mice. In the therapeutic
setting, there was a 40 to 50% survival rate among
tumor-bearing mice at day 50 while all mice in control
groups (including those that had received the mouse
MMP-2 vaccine) had died by day 40. Depletion of CD4+
cells in tumor-bearing mice eliminated the anti-tumor
efficacy of the cMMP-2 vaccine, whereas depletion of
CD8+ or NK cells had no effect. Further evidence that
the anti-tumor effect was mediated by CD4+ cell activa-
tion came from adoptive transfer experiments in which
purified antibodies from cMMP-2-vaccinated mice
blocked transmigration of tumor and endothelial cells in
vitro, inhibited angiogenesis in the chick chorio-allantoic
membrane assay, and reduced tumor growth in vivo.
Although this pre-clinical study shows promise, earlier
clinical trials with MMP inhibitors have been disap-
pointing, perhaps because of their broad spectrum of
inhibitory activity [124-126]. In addition to MMP-2,
pre-clinical experiments investigating the efficacy of vac-
cines targeting MMP-1 and -7 for their anti-tumor
activity warrant consideration [127].
Integrins Neovascular endothelial cells in tumor tissues
express proteins not present or not readily detectable in
quiescent vascular endothelial cells, such as avb3 integ-
rins. Integrins, comprised of a and b subunits, are het-
erodimeric cell-surface-adhesion receptors that bind to
the extracellular matrix (ECM) and that are essential for
tumor cell and endothelial cell growth. The avb5 and
avb3 are key integrins in promoting angiogenesis and
several inhibitors directed against these integrins have
shown an anti-angiogenic effect [128]. A xenogeneic
DNA vaccine encoding the ligand-binding domain of
chicken integrin b3 was tested for its anti-tumor activity
in several tumor models in mice [129]. In both protec-
tive and therapeutic immunity models, the vaccine
demonstrated anti-tumor activity through induction of
CD4+-dependent antibodies. Purified immunoglobulins
against b3 integrin inhibited endothelial cell prolifera-
tion in vitro and possessed anti-tumor and anti-angio-
genic activity by adoptive transfer in vivo.
Adverse Effects
Except for delayed wound healing and decreased ferti-
lity, investigators in the vast majority of studies reported
no morbidity in mice administered vaccines targeting
endothelial cells [38,47,51,62,73,78,82,94,96]. These stu-
dies ranged from endothelial cell vaccines to defined
endothelial targets such as MMP-2, VEGFR2, FGFR-1,
or endogolin [50,51,87,123]. Vaccinated mice targeting
the tumor endothelium were noted to have a normal
physical appearance, normal life span, no weight loss, no
signs of distress, no bleeding disorders, and have no
pathological changes in their tissues [50,55,59,83,87,
115,123,130]. In only one study did the vaccinated mice
appear to show a change in their physical habitus: in
this report, mice vaccinated with DC pulsed with a
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a change in their behavior [65].
Because cross-reactivity with physiologic angiogenic
targets was a primary concern with this vaccination
strategy, wound healing and fertility were carefully
investigated in several studies. Some vaccines targeting
VEGFR2, FGFR-1, and endogolin resulted in delayed
wound healing [43,59,78,87]. Niethammer et al specifi-
cally commented about the delay in wound healing
which was quite modest in vaccinated mice – 13 days
for control mice vs 14 days for vaccinated mice for
complete closure of wound [45]. For pregnancy experi-
ments, studies noted decreased fertility in mice immu-
nized with VEGFR2-targeted vaccines [43,45,47]. For
example, Nair and colleagues found a moderate effect
on fertility with the vaccine in which litter size returned
to normal 8 weeks post- vaccination [47]. A more
marked effect on fertility was shown with a DC vaccine
that had been pulsed with a VEGFR2-alkaline phospha-
tase fusion protein [45]. The litter size in these mice
was decreased to 2 (compared to 6 in the wild-type
group) and the mice born were either still born or lived
for 10 days. Interestingly, the DC-VEGFR2 fusion pro-
tein vaccine had no effect on wound healing.
In contrast to most VEGFR2 vaccines that had an
effect on either wound healing and/or fertility, the
VEGFR2 DNA vaccine delivered by the Listeria was
devoid of delayed wound healing and decreased fertility
[32]. Moreover, other angiogenic vaccines including
those targeting VEGF-A [47,73], HMW-MAA [33],
bFGF [77], TEM8 [83], and survivin vaccines [35] had
no effects on wound healing and/or fertility. Although
the angiogenic target no doubt plays a role in these side
effects (or lack of), the route and delivery vector are
likely important contributors to these unwanted side
effects. For example, the endothelial DNA vaccines
delivered by bacteria were remarkably free of side effects
including delayed wound healing and reduced fertility;
indeed 4 of the 5 orally delivered bacteria vaccines tar-
geting different angiogenic targets, which examined
wound healing and/or fertility, had no side effects
[32,33,35,83]; the bacterial vaccine that affected physio-
logic angiogenesis delayed wound healing minimally
with no effect on fertility [45]. Toxicity profiles of many
other delivery systems (e.g., electroporation) cannot be
fully evaluated because wound healing and fertility stu-
dies have not been done.
That anti-angiogenic agents such as Avastin have been
well tolerated gives us cautious optimism that other
anti-angiogenic strategies such as the use of vaccines
may be similarly well-tolerated. Nevertheless, it is clear
that the anti-angiogenic agents may have unanticipated
side effects beyond their effects on tumor growth, bleed-
ing diathesis, fertility, and wound healing [131]. The
side effects of Avastin, thought to be due to its anti-
VEGF action, including hypertension, proteinuria, and
thrombosis have not been reported for endothelial vac-
cines [131], but it would not be surprising if some of
these side effects occur with VEGF/VEGFR2 targeted
vaccines. In summary, the lack of significant toxicity
reported by tumor endothelial vaccine pre-clinical stu-
dies is encouraging, but circumspection to this vaccine
approach is needed based on potential toxicities con-
cerning physiologic angiogenesis and vascular
homeostasis.
Conclusion
Significant resources including numerous pre-clinical
and clinical studies have been devoted to the develop-
ment of tumor vaccines. Thus far, these results have
progressed and culminated in the approval a vaccine
targeting advanced prostate cancer (Provenge). Although
the benefits with this FDA-approved vaccine are modest,
further improved vaccine versions are no doubt on the
horizon and will aid with other vaccines approaches,
including those against the tumor endothelium. Com-
pared to tumor vaccines, the number of varied
approaches for tumor endothelial vaccines is relatively
limited and is currently restricted to pre-clinical experi-
ments and primarily phase I trials.
As discussed in this review, several studies with tumor
endothelial vaccines show anti-tumor efficacy in both
transplantable and transgenic tumor-bearing animal
models. Of particular note were the bacteria-based vac-
cines that showed marked anti-tumor response with var-
ied anti-angiogenic genes and few if any side effects.
Nevertheless, major obstacles still remain, including iden-
tification and validation of specific targets on the tumor
endothelium, inhibition of local suppression mechanisms,
and boosting anti-tumor immunity through NK cells
[132]. Thus far, there have been few data from the
endothelial vaccine studies on the various T-cell sub-
types, including regulatory T-cells or myeloid derived
suppressor cells [25,133,134], and comparison of T-cell
subtypes in the tumor and peripheral tissues may be use-
ful in development of more effective vaccines. Other
immune cells such as NK cells have not yet shown a
direct role in augmenting the efficacy of tumor endothe-
lial vaccines [64,87,94,130], but more research examining
interactions among NK cells, dendritic cells, and immu-
nomodulatory agents is needed [132,135,136].
Since tumor angiogenesis is a complex process, target-
ing a single epitope is unlikely to be successful. In many
cases, the treated tumor adapts and finds alternative
mechanisms of tumorigenesis eventually leading to resis-
tance to therapy. Thus, combinations of anti-angiogenic
vaccines with existing chemotherapy or immunomodula-
tory therapies offer interesting and exciting possibilities.
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combinatory treatments between vaccines and IL-12,
GM-CSF, CCL21, or b-defensins markedly increased the
immune response toward tumor endothelial cells
[39,41,62,64]. Nevertheless, these co-stimulatory thera-
pies have been used sparingly and other commonly used
c y t o k i n e ss u c ha sI L - 2 ,I F Na or b [137-139] have not
been co-administered or transfected into immune and/
or endothelial cells to augment vaccine efficacy. More-
over, considerable more research is needed to determine
the optimal co-stimulatory therapy to be administered
with the vaccine for the different delivery methods.
Another consideration in developing anti-angiogenic
vaccines is their potential for causing complications.
Cross-reactivity between tumor and non-tumor disease
tissues due to tumor endothelial vaccine may result in
reduced compensatory biological processes. The classic
tumor endothelial target is VEGFR2 up-regulated not
only in the endothelial vessels of tumors but also in
healing wounds and hypoxic cardiac tissues. Interest-
ingly, at least with 4 vaccine studies (VEGFR2, VEGF-A,
bFGF, survivin/CCL21) tumor angiogenesis was mark-
edly inhibited, but these vaccines did not interfere with
normal physiologic processes in several studies
[32,35,47,76,77]. The mechanism whereby tolerance to
self-angiogenic antigens in tumors but not in normal
angiogenic processes is broken remains unknown. It has
been suggested that differences in breaking self-angio-
genic antigen tolerance between tumors and normal
physiological processes may be based on the difference
of their vascular organization [32,140]; determining
whether or not this is the mechanism for this difference
will require further study.
To ensure effective tumor eradication and reduce
autoimmune side effects, intensive efforts are still
needed to identify additional targets specific to the
tumor endothelium. One such study recently found
highly specific and expressed markers of the tumor
endothelium that were not expressed in quiescent blood
vessels or physiologic angiogenesis [13]. Nevertheless,
the efficacy of vaccines against these new markers has
not yet been determined. Alternatively, finding tissue-
specific vascular targets (e.g., prostate) may enable
development of tumor endothelial vaccines with accep-
table side effects [141,142]. There is also the possibility
that tailored endothelial vaccines may be developed
based on specific endothelial epitopes associated with
certain tumors [143]. As new anti-angiogenic targets are
discovered, we anticipate that promising new therapeu-
tic approaches are on the horizon.
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